Announcement: Semaglutide Approved for Advanced Liver Disease: First GLP-1 Drug to Treat MASH with Fibrosis

Last updated: 24/09/2026 05:26

0 Min Read

Semaglutide (Wegovy) has become the first glucagon-like peptide-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. This approval expands GLP-1 therapeutics beyond metabolic disease into hepatology and addresses a critical unmet need in progressive liver disease management. — Photo by Haberdoedas on Unsplash (Unsplash License)

1 min read|55 words

Breaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. This approval marks a major shift in liver disease management, offering disease-modifying therapy to millions at risk of cirrhosis. Read the clinical implications for patients, clinicians, and health systems.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: Semaglutide Approved for Advanced Liver Disease: First GLP-1 Drug to Treat MASH with Fibrosis →

Share This Article

ByProf. Giorgi Pkhakadze, MD, MPH, PhD

Follow:

MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.